Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach.

We report the clinical evolution of a prostate cancer, metastasizing to lungs and bones, recurring locally, and escaping from anti-androgen therapy. Key event of biological progression of the patient's tumor was the coincidence of allelic imbalance accumulation and of bone metastases occurrence. The recurrent tumor was established as the transplantable xenograft PAC120 in nude mice, where it grew locally. PAC120 displayed the same immunophenotype of the original tumor (positive for keratin, vimentin, prostatic acid phosphatase, and Leu-7) and expressed human HOXB9, HOXA4, HER-2/neu, and prostate-specific antigen genes, as detected by reverse transcriptase-polymerase chain reaction. It formed lung micrometastases detected by mRNA expression of human genes. Cytogenetic analysis demonstrated numerous alterations reflecting the tumor evolution. PAC120 was still hormone-dependent; its growth was strongly inhibited by the new gonadotropin-releasing hormone antagonist FE 200486 but weakly by gonadotropin-releasing hormone superagonist D-Trp(6)-luteinizing-hormone releasing hormone (decapeptyl). Tumor growth inhibition induced by anti-hormone therapy was linked to the hormone deprivation degree, more important and more stable with FE 200486 than with D-Trp(6)-luteinizing-hormone releasing hormone. Surgical castration of mice led to tumor regressions but did not prevent late recurrences. Transition to hormone-independent tumors was frequently associated with a mucoid differentiation or with a neuroendocrine-like pattern. Independent variations of mRNA expression of HER-2/neu and prostate-specific antigen were observed in hormone-independent tumors whereas HOXB9 gene expression was constant. In conclusion, PAC120 xenograft, a new model of hormone-dependent prostate cancer retained the progression potential of the original tumor, opening the opportunity to study the hormone dependence escape mechanism.

[1]  B. Dutrillaux,et al.  Conservation of replication chronology of homologous chromosome bands between four species of the genus Cebus and man. , 1981, Cytogenetics and cell genetics.

[2]  A. Schally,et al.  Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Sandberg.  Chromosomal abnormalities and related events in prostate cancer. , 1992, Human pathology.

[4]  T. H. van der Kwast,et al.  Development of seven new human prostate tumor xenograft models and their histopathological characterization. , 1996, The American journal of pathology.

[5]  W. Isaacs,et al.  Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. , 1996, Cancer research.

[6]  T. H. van der Kwast,et al.  Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. , 1987, Journal of the National Cancer Institute.

[7]  R. Kirby,et al.  Ki-67 expression in early prostate cancer and associated pathological lesions. , 1996, Journal of clinical pathology.

[8]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.

[9]  T. Libermann,et al.  PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene Expression* , 2000, The Journal of Biological Chemistry.

[10]  J. Isaacs,et al.  The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.

[11]  B. Dutrillaux,et al.  Cytogenetic study of 30 colorectal adenomas. , 1994, Cancer genetics and cytogenetics.

[12]  J. Clements,et al.  Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer. , 1999, The Journal of urology.

[13]  L. McWilliam,et al.  Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. , 1997, British journal of urology.

[14]  D. Treré,et al.  Chromosome 1 aneusomy with 1p36 under‐representation is related to histologic grade, DNA aneuploidy, high c‐erb B‐2 and loss of bcl‐2 expression in ductal breast carcinoma , 1996, International journal of cancer.

[15]  M. Resnick,et al.  Xenografts of primary human prostatic carcinoma. , 1993, Journal of the National Cancer Institute.

[16]  Y. Nakazato,et al.  A new serially transplantable human prostatic cancer (HONDA) in nude mice. , 1984, The Journal of urology.

[17]  E. Olapade-Olaopa,et al.  Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer , 1999, British Journal of Cancer.

[18]  Grignon Dj,et al.  Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? , 1994 .

[19]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[20]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[21]  P. Schellhammer,et al.  Cytogenetic evaluation of 20 cultured primary prostatic tumors. , 1991, Cancer genetics and cytogenetics.

[22]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[23]  D. S. Coffey.  Prostate cancer. An overview of an increasing dilemma , 1993, Cancer.

[24]  H. Höfler,et al.  Combined cytogenetic and molecular genetic analyses of fifty-nine untreated human prostate carcinomas. , 1996, Cancer genetics and cytogenetics.

[25]  D. Neal,et al.  aFGF immunoreactivity in prostate cancer and its co‐localization with bFGF and FGF8 , 1999, The Journal of pathology.

[26]  C. Griffin,et al.  Cytogenetic abnormalities are frequent in uncultured prostate cancer cells. , 1996, Cancer genetics and cytogenetics.

[27]  D. Djakiew.  Dysregulated expression of growth factors and their receptors in the development of prostate cancer , 2000, The Prostate.

[28]  Atkin Nb,et al.  Chromosome 10 deletion in carcinoma of the prostate. , 1985 .

[29]  S. Sentinelli.  Mucins in prostatic intra‐epithelial neoplasia and prostatic carcinoma , 1993, Histopathology.

[30]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[31]  J. Schleutker,et al.  Androgen receptor gene mutations in hormone‐refractory prostate cancer , 1999, The Journal of pathology.

[32]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[33]  R. Vessella,et al.  Preclinical models of prostate cancer. , 1996, Seminars in oncology.

[34]  B. Dutrillaux,et al.  The accumulation and occurrence of clonal and unstable rearrangements are independent in colorectal cancer cells. , 1996, Cancer genetics and cytogenetics.

[35]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[36]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[37]  D. S. Coffey,et al.  Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. , 1981, Cancer research.

[38]  P. Hermanek,et al.  Prostatic adenocarcinoma PC EW, a new human tumor line transplantable in nude mice , 1984, The Prostate.

[39]  V. Castronovo,et al.  Expression and modulation of homeobox genes from cluster B in endothelial cells. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[40]  P. Walsh,et al.  Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. , 1993, Cancer research.

[41]  A. Belldegrun,et al.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.

[42]  K. Griffiths,et al.  Endocrine treatment of prostate cancer. , 1989, Progress in medicinal chemistry.

[43]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Poupon,et al.  Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. , 1993, Journal of the National Cancer Institute.

[45]  A. Schally,et al.  Luteinizing hormone–releasing hormone (LH–RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors , 1998, Regulatory Peptides.

[46]  A. Schally,et al.  GRHきっ坑薬のMZ‐5‐156は,ヌードマウスのDU‐145ヒトアンドロゲン非依存性前立腺癌の成長を阻害し,腫よう内のIGF2のレベル及びmRNA発現を低下させる , 1998 .

[47]  H. Klocker,et al.  Regulation of prostatic growth and function by peptide growth factors , 1996, The Prostate.

[48]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[49]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[50]  P. Hermanek,et al.  Human prostatic adenocarcinoma: Some characteristics of a serially transplantable line in nude mice (PC 82) , 1980, The Prostate.

[51]  J. Epstein,et al.  Mucinous adenocarcinoma of the prostate gland. , 2014, The Ceylon medical journal.

[52]  B. Barrell,et al.  Sequence analysis and in vitro transcription of portions of the epstein‐barr virus genome , 1982, Journal of cellular biochemistry.